Outcome Measures for Chronic Inflammatory Demyelinating Polyneuropathy in Research: Relevance and Applicability to Clinical Practice

References

• Breiner A , BarnettC, BrilV. Incat disability score: a critical analysis of its measurement properties. Muscle Nerve, 50(2), 164–169 (2014).
   PubMed Web of Science ®Google Scholar
• Anon. Aids to the investigation of peripheral nerve injuries. J. Neurol. Psychiatry, 6(1–2), 81 (1943).
   Google Scholar
• Vanhoutte EK , FaberCG, van NesSIet al. Modifying the medical research council grading system through Rasch analyses. Brain, 135(5), 1639–1649 (2012).
   PubMedGoogle Scholar
• Dyck PJ , TurnerDW, DaviesJLet al. Electronic case-report forms of symptoms and impairments of peripheral neuropathy. Can. J. Neurol. Sci., 29(3), 258–266 (2002).
   PubMed Web of Science ®Google Scholar
• Rankin J . Cerebral vascular accidents in patients over the age of 60: I. General considerations. Scott. Med. J., 2(4), 127–136 (1957).
   PubMedGoogle Scholar
• Hughes RA , Newsom-DavisJM, PerkinGD, PierceJM. Controlled trial prednisolone in acute polyneuropathy. Lancet, 2(8093), 750–753 (1978).
   PubMed Web of Science ®Google Scholar
• Sharrack B , HughesRA. The Guy’s neurological disability scale (GNDS): a new disability measure for multiple sclerosis. Mult. Scler. J., 5(4), 223–233 (1999).
   PubMed Web of Science ®Google Scholar
• Merkies ISJ , SchmitzPIM, vander Meché FGA, SamijnJPA, van DoornPA, Inflammatory Neuropathy Cause and Treatment (INCAT) group. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J. Neurol. Neurosurg. Psychiatry, 72(5), 596–601 (2002).
   PubMed Web of Science ®Google Scholar
• Merkies IS , SchmitzPI, vander Meché FG, van DoornPA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. inflammatory neuropathy cause and treatment (INCAT) group. Neurology, 54(4), 943–949 (2000).
   PubMed Web of Science ®Google Scholar
• Graham RC , HughesRAC. A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J. Neurol. Neurosurg. Psychiatry, 77(8), 973–976 (2006).
   PubMed Web of Science ®Google Scholar
• van Nes SI , VanhoutteEK, van DoornPAet al. Rasch-built overall disability scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology, 76(4), 337–345 (2011).
   PubMed Web of Science ®Google Scholar
• Rajabally YA , NarasimhanM. Jamar hand-held grip dynamometry in chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci., 325(1–2), 36–38 (2013).
   PubMed Web of Science ®Google Scholar
• Draak THP , PruppersMHJ, van NesSIet al. Grip strength comparison in immune-mediated neuropathies: Vigorimeter vs. Jamar. J. Peripher. Nerv. Syst., 20(3), 269–276 (2015).
   PubMed Web of Science ®Google Scholar
• Harbo T , MarkvardsenLK, HellfritzschMB, SeverinsenK, NielsenJF, AndersenH. Neuromuscular electrical stimulation in early rehabilitation of Guillain-Barre Syndrome: a pilot study. Muscle Nerve, 59(4), 481–484 (2018).
   Web of Science ®Google Scholar
• Dyck PJ , LitchyWJ, KratzKMet al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol., 36(6), 838–845 (1994).
   PubMed Web of Science ®Google Scholar
• Hahn AF , BoltonCF, ZochodneD, FeasbyTE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain, 119(Pt 4), 1067–1077 (1996).
   PubMedGoogle Scholar
• Mendell JR , BarohnRJ, FreimerMLet al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology, 56(4), 445–449 (2001).
   PubMed Web of Science ®Google Scholar
• Vermeulen M , van DoornPA, BrandA, StrengersPF, JennekensFG, BuschHF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry, 56(1), 36–39 (1993).
   PubMed Web of Science ®Google Scholar
• Thompson N , ChoudharyP, HughesRA, QuinlivanRM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol., 243(3), 280–285 (1996).
   PubMed Web of Science ®Google Scholar
• Hughes R , BensaS, WillisonHet al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol., 50(2), 195–201 (2001).
   PubMed Web of Science ®Google Scholar
• Hughes RA , DonofrioP, BrilVet al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol., 7(2), 136–144 (2008).
   PubMed Web of Science ®Google Scholar
• RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol., 8(2), 158–164 (2009).
   PubMed Web of Science ®Google Scholar
• Kuitwaard K , vanden Berg LH, VermeulenMet al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. Neurosurg. Psychiatry, 81(12), 1374–1379 (2010).
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E , CocitoD, JannSet al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol., 11(6), 493–502 (2012).
   PubMed Web of Science ®Google Scholar
• Camdessanche J-P , FerraudK, LagrangeEet al. Multicentre, randomised, open-label trial to compare efficacy and tolerance of prednisone and IVIG in patients with CIDP on a one year follow up (P7.092). Neurology, 82(Suppl. 10), Abstract P7.092 (2014).
   Google Scholar
• Markvardsen LH , HarboT. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs. J. Neurol. Sci., 378, 19–25 (2017).
   PubMed Web of Science ®Google Scholar
• Kuwabara S , MoriM, MisawaSet al. Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week Phase III trial. J. Neurol. Neurosurg. Psychiatry, 88(10), 832–838 (2017).
   PubMed Web of Science ®Google Scholar
• van Schaik IN , BrilV, van GelovenNet al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet Neurol., 17(1), 35–46 (2018).
   PubMed Web of Science ®Google Scholar
• Dyck PJ , O’BrienPC, OviattKFet al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann. Neurol., 11(2), 136–141 (1982).
   PubMed Web of Science ®Google Scholar
• van Schaik IN , EftimovF, van DoornPAet al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol., 9(3), 245–253 (2010).
   PubMed Web of Science ®Google Scholar
• Dyck PJ , DaubeJ, O’BrienPet al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N. Engl. J. Med., 314(8), 461–465 (1986).
   PubMed Web of Science ®Google Scholar
• Hahn AF , BoltonCF, PillayNet al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain, 119(Pt 4), 1055–1066 (1996).
   PubMedGoogle Scholar
• Rai SK , YazdanyJ, FortinPR, Aviña-ZubietaJA. Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. Arthritis Res. Ther., 17(1), 143 (2015).
   PubMedGoogle Scholar
• Jaeschke R , SingerJ, GuyattGH. Measurement of health status. Ascertaining the minimal clinically important difference. Control. Clin. Trials, 10(4), 407–15 (1989).
   PubMedGoogle Scholar
• Engel L , BeatonDE, ToumaZ. Minimal clinically important difference. Rheum. Dis. Clin. North Am., 44(2), 177–188 (2018).
   PubMed Web of Science ®Google Scholar
• Eftimov F , VermeulenM, van DoornPA, BrusseE, van SchaikIN. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology, 78(14), 1079–1084 (2012).
   PubMed Web of Science ®Google Scholar
• Merkies ISJ , van NesSI, HannaK, HughesRAC, DengC. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J. Neurol. Neurosurg. Psychiatry, 81(11), 1194–1199 (2010).
   PubMed Web of Science ®Google Scholar
• Spina E , TopaA, IodiceRet al. Six-minute walk test is reliable and sensitive in detecting response to therapy in CIDP. J. Neurol., 266(4), 860–865 (2019).
   PubMed Web of Science ®Google Scholar
• Fukumori N , YamamotoY, TakegamiMet al. Association between hand-grip strength and depressive symptoms: locomotive syndrome and health outcomes in Aizu cohort study (LOHAS). Age Ageing, 44(4), 592–598 (2015).
   PubMed Web of Science ®Google Scholar
• Eftimov F , WinerJB, VermeulenM, de HaanR, van SchaikIN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. In: Cochrane Database of Systematic Reviews.van SchaikIN. ( Ed.). John Wiley & Sons, Ltd, Chichester, UK, CD001797 (2009).
   Google Scholar
• Wimperis J , LunnM, JonesAet al. Clinical guidelines for immunoglobulin use. Second edition update (2011). https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216671/dh_131107.pdf
   Google Scholar
• Gwathmey KG , SadjadiR, HortonWBet al. Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy. Neurology, 90(23), e2034–e2041 (2018).
   PubMed Web of Science ®Google Scholar
• Bjelica B , PericS, GwathmeyKet al. Chronic acquired polyneuropathy patient reported index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst., 24(3), 247–252 (2019).
   PubMed Web of Science ®Google Scholar